Learn more about the benefits of early sodium-glucose cotransporter 2 inhibitor initiation for heart failure patients, both in the acute and chronic settings, in improving CV and hospitalization outcomes and mitigating the damage of upstream cardio-renal-metabolic (CRM) risk factors.

Learn more about cardio-renal-metabolic (CRM) diseases, including type 2 diabetes mellitus (T2D), diabetic kidney disease (DKD) and heart failure (HF), and the effectiveness of empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), in mitigating cardiovascular and mortality risks and preserving kidney function.

Watch this webinar to learn more about the new classification system for chronic obstructive pulmonary disease (COPD) in the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Select the right therapy in the form of dual long-acting bronchodilator combination with a long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA), and tailor the choice of inhaler device to your patients. 

Learn more about the role of dual bronchodilator, long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA), in chronic obstructive pulmonary disease (COPD) based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report (i.e., version 2024) and how to improve clinical outcome in COPD through selection of inhaler device.

Learn more about the latest international COPD guidelines recommendations for individualizing COPD management and optimizing patient outcomes with LABA/LAMA combination therapy.